Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2014, Vol. 34 Issue (8): 24-28    DOI: 10.13523/j.cb.20140804
    
Preparation and Characterization of Polyclonal Antibody Against CD133 Derived from Camel
ZHAI Tian-tian, MA Xiao-ling, Muyassar, M LI Ling-xia, LI Jiang-wei
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830046, China
Download: HTML   PDF(646KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: The purpose is confirming and acquiring of high titer anti-CD133 antibodies from immunized camel, and providing the basis for preparing anti-CD133 nanobody. Methods: The gene segment coding of CD133 extracellular region were PCR amplified and ligated into pET28a plasmid and construction of a prokaryotic expression vector. The recombinant CD133 protein was expressed by IPTG induction and purified with Ni-affinity chromatography. A male Bactrian camel and two New Zealand rabbits were immunized with purified rCD133 antigen respectively. The enzyme-linked immunosorbent (ELISA) and Western blotting were applied to assay the titer of polyclonal antibody and the specific binding to CD133 protein. Results: the ELISA results revealed that the titer of anti-CD133 antibody raised from camel reached about 1:106 after the 5th immunization, and the titer of anti-CD133 antibody raised from rabbit reached about 1:5×105 after the 4th immunization.The anti-CD133 antisera could bind rCD133 specifically in Western blotting. Conclusion: The high titer anti-CD133 polyclonal antibodies were raised in camel compared with rabbit and it lay a good foundation for the future experiment.



Key wordsCD133      Polyclonal antibody      Bactrian camel      Cancer stem cell     
Received: 18 June 2014      Published: 25 August 2014
ZTFLH:  Q786  
Cite this article:

ZHAI Tian-tian, MA Xiao-ling, Muyassar, M LI Ling-xia, LI Jiang-wei. Preparation and Characterization of Polyclonal Antibody Against CD133 Derived from Camel. China Biotechnology, 2014, 34(8): 24-28.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20140804     OR     https://manu60.magtech.com.cn/biotech/Y2014/V34/I8/24


[1] Soltanian S, Matin M M. Cancer stem cells and cancer therapy. Tumor Biol, 2011, 32(3): 425-440.

[2] Jin X, Jung J E, Beck S, et al. Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun, 2013, 433(4): 496-501.

[3] Boman B M, Wicha M S. Cancer stem cells: a step toward the cure. Clin Oncol, 2008, 26(17): 2795-2799.

[4] Ferrandina G, Petrillo M, Bonanno G, et al. Targeting CD133 antigen in cancer. Expert Opin Ther Targets, 2009, 13(7): 823-837.

[5] Bao S, Wu Q, McLendon R E, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444: 756-760.

[6] Naujokat C. Monoclonal antibodies against human cancer stem cells. Immunotherapy, 2014, 6(3): 290-308.

[7] Smith L M, Nesterova A, Ryan M C, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer, 2008, 99(1): 100-109.

[8] Akita M, Tanaka K, Murai N, et al. Detection of CD133 (prominin-1) in a human hepatoblastoma cell line (HuH-6 clone 5). Microsc Res Tech, 2013, 76(8): 844-852.

[9] Chen H, Luo Z, Sun W, et al. Low glucose promotes CD133mAb-elicited cell death via inhibition of autophagy in hepatocarcinoma cells. Cancer Lett, 2013, 336(1): 204-212.

[10] John R Ohlfest, David M. Immunotoxin targeting CD133+ breast carcinoma cells. Drug Deliv Transl Res, 2013, 3: 195-204.

[11] Skubitz A P, Taras E P, Boylan K L, et al. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecologic Oncology, 2013, 130 (3): 579-587.

[12] De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol, 2014, 32(5): 263-270.

[13] Griffin L M, Snowden J R, Lawson A D, et al. Analysis of heavy and light chain sequences of conventional camelid antibodies from Camelus dromedarius and Camelus bactrianus species. J Immunol Methods, 2014, 405: 35-46.

[14] van der Linden R, de Geus B, Stok W, et al. Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J Immunol Methods, 2000, 240(1-2): 185-195.

[15] 夏丽洁, 苏幼红, 张清华, 等. 新疆双峰驼抗血清中重链抗体的分离鉴定. 中国农业科学, 2010, 43(17): 3660-3666. Xia L J, Su Y H, Zhang Q H, et al. Isolation and identification of heavy chain antibodies derived from immunized xinjiang Camelus bactrianus. Scientia Agricultura Sinica, 2010, 43(17): 3660-3666.

[16] 夏丽洁, 苏幼红, 晏鹏飞, 等. 采用双峰驼重链抗体特异的抗血清检测不同抗原免疫骆驼过程中血清重链抗体的水平. 中国畜牧兽医, 2012, 39(4): 68-72. Xia L J, Su Y H, Yan PF, et al. The dynamic change of heavy chain antibody in Camelus bactrianus during the immunization with different antigens assayed by heavy chain antibody specific antiserum. China Animal Husbandry and Veterinary Medicine, 2012, 39(4): 68-72.

[1] CHEN Xiu-yue,ZHOU Wen-feng,HE Qing,SU Bing,ZOU Ya-wen. Preparation, Purification and Identification of Bacteriophage Qβ Virus-like Particles[J]. China Biotechnology, 2021, 41(7): 42-49.
[2] CHEN Qiu-li,YANG Li-chao,LI Hui,WEN Sha,LI Gang,HE Min. Prokaryotic Expression,Purification and Preparation of Polyclonal Antibody of Human Nek2 Protein[J]. China Biotechnology, 2020, 40(3): 31-37.
[3] Yu-han CHENG,Xi GONG,Yu-ping LUO. Advances in Studies on the Structure, Function and Related Antibodies of CD133 (Prominin-1)[J]. China Biotechnology, 2019, 39(5): 105-113.
[4] Ming-ming HAN,Yu-ping LUO. Establishment and Identification of Endogenous CD133 + Cell Tracer Mouse Model[J]. China Biotechnology, 2018, 38(6): 58-62.
[5] QIN Rui-ping, LI Ling-xia, MA Xiao-ling, XI Ou-yan, ZHAO Ting, QIU Ling-ling, LI Jiang-wei. Inhibition of Osteoporosis in Ovariectomized Rats Using Follicle-stimulating Hormone Receptor Specific Polyclonal Antibody[J]. China Biotechnology, 2017, 37(6): 9-16.
[6] LIU Yan-Xia, FAN Zhen-Chuan. Polyclonal Antibody Preparation and Application of C.reinhardtii LZTFL1 Protein[J]. China Biotechnology, 2017, 37(11): 109-115.
[7] DAI Shuang, ZHAO Qing-qing, QIU Feng. Transfection Efficiency Using PEI-CP Complex for CD133+ Differently Expressed by Colon Cancer Lines[J]. China Biotechnology, 2016, 36(6): 32-38.
[8] YANG Si-yuan, PAN Jing-mei, WANG Shuo, DENG Kai-xuan, DENG Qiang, HUANG Xin-he, LI Xue-ru. The Preparation of the Streptolysin O Active Recombinant Protein of Streptococcus pyogenes[J]. China Biotechnology, 2016, 36(6): 51-56.
[9] CHEN Xiao-feng, HU Pan, LI Yan-song, GUO Xing, ZOU De-ying, LIU Nan-nan, LU Shi-ying, ZHOU Yu, LIU Zeng-shan, LI Zhao-hui, REN Hong-lin. Molecular Cloning, Prokaryotic Expression and Polyclonal Antibody Preparation of Peroxiredoxin 6 (Prdx6) from Mus musculus[J]. China Biotechnology, 2016, 36(3): 11-16.
[10] LIAO He-bin, LIU Ma-feng, CHENG An-chun. The Assessment of RecA Acted as an Internal Reference Protein in R. anatipestifer[J]. China Biotechnology, 2015, 35(6): 26-31.
[11] MENG Shu-lin, MA Bu-yun, ZHANG Xin-min, GE Yun, ZHANG Rong, HUANG Pan-pan, WANG Yi-gang. Killing Effects of Thioridazine on Liver Cancer Stem Cell[J]. China Biotechnology, 2015, 35(2): 8-17.
[12] XU Ying-chen, GUAN Li-dong, ZHOU Jun-nian, ZENG Quan, YUAN Hong-feng, LI Si-ting, GUAN Zhao-xuan, HE Li-juan, NAN Xue, CHEN Lin, YUE Wen, PEI Xue-tao. Isolation and Identification of Liver Cancer Stem Cells and Analysis of Differentially Expressed MicroRNAs[J]. China Biotechnology, 2013, 33(1): 1-7.
[13] LI Xiao, LIU Liu, ZHANG Lei, ZHOU Ya-jing. Production and Application of Polyclonal Antibody against p12, the Fourth Subunit of Human DNA Polymerase δ[J]. China Biotechnology, 2012, 32(05): 12-18.
[14] WANG Chun-hui, WANG Jian-song, WANG Wen-ju, ZHAN Hui, LI Hong-jun, YAN Ru-ping, XU Hong-yi. Preparation and Evaluation of Polyclonal Antibodies of Apoptin[J]. China Biotechnology, 2011, 31(7): 38-44.
[15] LIN Jie, MA Lan, ZHANG Shi-yi, GUAN Chang-dong, LI Xuan, LV Qi. Prokaryotic Expression of Human CD24 and Its Polyclonal Antibody Preparation[J]. China Biotechnology, 2011, 31(12): 39-45.